Faster global financial news!
Moderna
-
Moderna's Cancer Vaccine Rally Triggers Rare "Sell" Rating, Stock Expected to Fall 45%
Moderna's Cancer Vaccine Rally Triggers Rare "Sell" Rating, Stock Expected to Fall 45%
-
Wall Street analysts upgraded Broadcom, Deere, and Dell, while downgrading Moderna.
Macquarie upgraded Broadcom to Outperform with a $490 price target; Evercore ISI upgraded Deere & Company to Outperform with an $813 price target; Fox Advisors upgraded Dell Technologies to Outperform
-
Moderna Led the S&P 500 in August as Edison International Sank
Moderna Led the S&P 500 in August as Edison International Sank
-
Moderna shares surged 152% in August, leading S&P 500's 2.5% gain as software industry continued recovery
Moderna shares surged 152% in August, leading S&P 500's 2.5% gain as software industry continued recovery
-
Hypothetical S&P 500 Strategy Turns $100,000 Into $12.7 Million in 8 Months
A hypothetical investment strategy, involving investing $100,000 in January into the S&P 500's top-performing stock and re-investing monthly into each subsequent month's best performer, would have yie
-
Wall Street's momentum trading strategies have suddenly unraveled, with the S&P 500 Momentum Index falling over 9% since July, facing its worst quarterly performance in 25 years.
The Wall Street Journal reported on August 30 that the once-popular "momentum trading" strategy (buying rising stocks and shorting falling stocks) has fallen by over 9% since July 1, after a strong pe
-
Argus Research upgraded Moderna (MRNA) to "Buy" with a price target of $180, making it the fifth institution to raise its rating recently.
Argus Research upgraded Moderna (MRNA) to "Buy" with a price target of $180, making it the fifth institution to raise its rating recently.
-
BioNTech shares tumble 8% after terminating Phase 2 colorectal cancer vaccine trial due to futility
BioNTech's stock fell to $102.38 after the company announced it had scrapped its Phase 2 BNT122-01 colorectal cancer vaccine trial, developed with Genentech, as an independent Data Safety Monitoring B
-
Moderna Plans $2 Billion Convertible Debt Offering to Support Cancer Vaccine Business and Repay Debt
Moderna Plans $2 Billion Convertible Debt Offering to Support Cancer Vaccine Business and Repay Debt
-
Moderna's market value of $63.7 billion is not supported by its shrinking commercial revenue of $2.2 billion, with the company's valuation resting on its drug pipeline.
Moderna's commercial business has contracted, with trailing-twelve-month revenue falling to $2.2 billion from $3.1 billion a year earlier, and an operating margin of -150.2%. The company's valuation i
-
Moderna shares drop 7% despite a recent Wolfe Research upgrade, while BioNTech slips 2%
Moderna (NASDAQ:MRNA) stock fell 7% to $148.02 midday Wednesday, giving back a large portion of Tuesday's 14% rally that followed Wolfe Research's upgrade to Peer Perform from Underperform. BioNTech S
-
Hong Kong-listed biotech firms accelerate Moderna-style cancer vaccine development amid market frenzy
Following Moderna's breakthrough cancer vaccine trial, Chinese companies including Jiangsu Hengrui Pharmaceuticals and Li Ka-shing-backed CK Life Sciences are pushing forward with similar programmes.
-
Jim Cramer: 'Give Me Anything But Tech' as Market Rotates from Data Centers to Enterprise Software, Pharma
Jim Cramer stated on CNBC's Squawk on the Street that the market is shifting away from technology, particularly data center-related plays, towards enterprise software and pharmaceutical companies. He
-
Moderna shares fall 7% to $135.22 as traders engage in profit-taking after a 392% year-to-date surge; BioNTech falls 4%, Merck falls 1%.
Moderna (MRNA) shares fell 7% to $135.22 in early trading Monday, after rising 392% year-to-date, as traders opted for profit-taking in the absence of new negative catalysts. Over the same period, Bio
-
US stocks fall, Dow drops over 1%; Walmart down 9% on weak earnings, Moderna plunges 24%
U.S. stocks closed lower on Wednesday, with the Dow Jones Industrial Average falling nearly 700 points, a drop of over 1%. Walmart's stock fell 9% after the company reported its smallest sales growth
-
Moderna Surges as Stocks Rise and Long-Term Yields Retreat
Moderna Surges as Stocks Rise and Long-Term Yields Retreat
-
Moderna Reports Second-Quarter Financial Results, with Revenue Exceeding Expectations and Profits for the Sixth Consecutive Quarter
Biotechnology company Moderna released its second-quarter 2026 financial results on July 31, reporting revenue of $389 million, exceeding the market’s consensus estimate of $236.36 million. This marks
-
Moderna's Cancer Vaccine Rally Triggers Rare "Sell" Rating, Stock Expected to Fall 45%
Moderna's Cancer Vaccine Rally Triggers Rare "Sell" Rating, Stock Expected to Fall 45%
-
Wall Street analysts upgraded Broadcom, Deere, and Dell, while downgrading Moderna.
Macquarie upgraded Broadcom to Outperform with a $490 price target; Evercore ISI upgraded Deere & Company to Outperform with an $813 price target; Fox Advisors upgraded Dell Technologies to Outperform
-
Moderna Led the S&P 500 in August as Edison International Sank
Moderna Led the S&P 500 in August as Edison International Sank
-
Moderna shares surged 152% in August, leading S&P 500's 2.5% gain as software industry continued recovery
Moderna shares surged 152% in August, leading S&P 500's 2.5% gain as software industry continued recovery
-
Hypothetical S&P 500 Strategy Turns $100,000 Into $12.7 Million in 8 Months
A hypothetical investment strategy, involving investing $100,000 in January into the S&P 500's top-performing stock and re-investing monthly into each subsequent month's best performer, would have yie
-
Wall Street's momentum trading strategies have suddenly unraveled, with the S&P 500 Momentum Index falling over 9% since July, facing its worst quarterly performance in 25 years.
The Wall Street Journal reported on August 30 that the once-popular "momentum trading" strategy (buying rising stocks and shorting falling stocks) has fallen by over 9% since July 1, after a strong pe
-
Argus Research upgraded Moderna (MRNA) to "Buy" with a price target of $180, making it the fifth institution to raise its rating recently.
Argus Research upgraded Moderna (MRNA) to "Buy" with a price target of $180, making it the fifth institution to raise its rating recently.
-
BioNTech shares tumble 8% after terminating Phase 2 colorectal cancer vaccine trial due to futility
BioNTech's stock fell to $102.38 after the company announced it had scrapped its Phase 2 BNT122-01 colorectal cancer vaccine trial, developed with Genentech, as an independent Data Safety Monitoring B
-
Moderna Plans $2 Billion Convertible Debt Offering to Support Cancer Vaccine Business and Repay Debt
Moderna Plans $2 Billion Convertible Debt Offering to Support Cancer Vaccine Business and Repay Debt
-
Moderna's market value of $63.7 billion is not supported by its shrinking commercial revenue of $2.2 billion, with the company's valuation resting on its drug pipeline.
Moderna's commercial business has contracted, with trailing-twelve-month revenue falling to $2.2 billion from $3.1 billion a year earlier, and an operating margin of -150.2%. The company's valuation i
-
Moderna shares drop 7% despite a recent Wolfe Research upgrade, while BioNTech slips 2%
Moderna (NASDAQ:MRNA) stock fell 7% to $148.02 midday Wednesday, giving back a large portion of Tuesday's 14% rally that followed Wolfe Research's upgrade to Peer Perform from Underperform. BioNTech S
-
Hong Kong-listed biotech firms accelerate Moderna-style cancer vaccine development amid market frenzy
Following Moderna's breakthrough cancer vaccine trial, Chinese companies including Jiangsu Hengrui Pharmaceuticals and Li Ka-shing-backed CK Life Sciences are pushing forward with similar programmes.
-
Jim Cramer: 'Give Me Anything But Tech' as Market Rotates from Data Centers to Enterprise Software, Pharma
Jim Cramer stated on CNBC's Squawk on the Street that the market is shifting away from technology, particularly data center-related plays, towards enterprise software and pharmaceutical companies. He
-
Moderna shares fall 7% to $135.22 as traders engage in profit-taking after a 392% year-to-date surge; BioNTech falls 4%, Merck falls 1%.
Moderna (MRNA) shares fell 7% to $135.22 in early trading Monday, after rising 392% year-to-date, as traders opted for profit-taking in the absence of new negative catalysts. Over the same period, Bio
-
US stocks fall, Dow drops over 1%; Walmart down 9% on weak earnings, Moderna plunges 24%
U.S. stocks closed lower on Wednesday, with the Dow Jones Industrial Average falling nearly 700 points, a drop of over 1%. Walmart's stock fell 9% after the company reported its smallest sales growth
-
Moderna Surges as Stocks Rise and Long-Term Yields Retreat
Moderna Surges as Stocks Rise and Long-Term Yields Retreat
-
Moderna Reports Second-Quarter Financial Results, with Revenue Exceeding Expectations and Profits for the Sixth Consecutive Quarter
Biotechnology company Moderna released its second-quarter 2026 financial results on July 31, reporting revenue of $389 million, exceeding the market’s consensus estimate of $236.36 million. This marks
- No data
Moderna
24H Trending
-
1
NOBI Token Value Analysis: Platform Transformation and Token Status
-
2
Databricks Chief Revenue Officer Ron Gabrisko stated that the company's annual recurring revenue (ARR) has grown from less than $1 million to over $7 billion, with approximately $1.7 billion of that coming from AI-related revenue.
-
3
IEA Says Ukraine Strikes Degrade Russian Oil-Refining Industry, With Sanctions Preventing Recovery from Drone Attacks
-
4
Bridgewater Associates Co-CIO Greg Jensen Compares Current AI Moment to February 2020
-
5
Anthropic Warns AI Could Be Used for Bioweapons, Has Blocked Several Related Attempts
-
6
Indonesian Builder PT PP to Restructure $1 Billion Bank Loans
-
7
a16z Partner: AI is pushing the "power law distribution" of tech investments to the extreme, traditional SaaS faces the risk of being abandoned by the era.
-
8
Neko Health CEO Hjalmar Nilsonne predicts AI and personalized medicine could help people live longer
-
9
AMB Coin: Founder, Project Evolution, and Current Price Analysis
-
10
Meta FPS (MFPS) Token Status: Trading Market and Project Background Analysis
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
